Bill
SB 3259
Rhode Island updates the Uniform Controlled Substances Act to modernize prescribing and monitoring of opioids, expand therapeutic use rules, and repeal the Intractable Pain Act.
Title: AN ACT RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
Jurisdiction: Rhode Island
Introduced by: Senator Melissa A. Murray
Referred to: Senate Health & Human Services
Date Introduced: May 5, 2026
Effective date: Upon passage
Overview and purpose
- This bill revises and updates Rhode Island’s Uniform Controlled Substances Act (the state’s framework for regulating controlled substances) to align with current professional practice standards and to repeal a prior framework for intractable pain treatment.
- It removes specific opioid dosage requirements and modifies definitions, regulatory triggers, and authorization structures related to prescribing, administering, and dispensing controlled substances.
Key provisions and changes
1) Definitions (Section 1)
- Repeals and restates the definitions section (21-28-1.02) with updated terminology and scope for schedules I–V controlled substances.
- Clarifies terms such as administering, dispensing, distributing, manufacturer, etc., and introduces or updates terms like “opiate,” “opioid analgesics,” “opioid antagonist,” “imitation controlled substance,” and “therapeutic purpose.”
- Expands guidance on what constitutes “administration,” “dispenser,” “ultimate user,” and related operational definitions used by health and law enforcement stakeholders.
- Updates references to federal law, the Prescription Drug Monitoring Program (PDMP), and recognized agencies (e.g., DEA, FDA, etc.).
2) Authority of practitioners to prescribe, administer, and dispense (Sections 21-28-3.20 and 21-28-3.20.1)
- Sets framework for prescribing, administering, and dispensing controlled substances for therapeutic purposes, including opioid therapies, with emphasis on safe practice and monitoring.
- Removes explicit prohibition on certain dosages for initial opioid prescriptions to a broad extent, replacing with department-set maximums and guidance (see subsections below).
- Establishes duties to review the PDMP prior to starting or refilling opioid therapy; requires checking history of methadone/buprenorphine use; and mandates documentation in the patient’s medical record for ongoing continuous opioid therapy (every three months after three months of treatment).
- Directs the Director of Health to promulgate regulations on opioid use in acute pain management, including initial prescriptions for adults not to exceed 30 morphine milligram equivalents (MMEs) per day and a cap of 20 doses for acute outpatient treatment, with pediatric-specific adjustments.
- Allows exceptions where clinical judgment warrants higher dosages or longer supply for specific scenarios (e.g., chronic pain management, cancer pain, sickle cell, palliative care) provided documentation supports the need and remains within department-imposed maximums.
3) Cancer, palliative care, and chronic intractable pain (Section 21-28-3.20.1)
- Provides a separate, flexible authority allowing practitioners to prescribe, administer, and dispense controlled substances for cancer-related pain, palliative care, chronic intractable pain, or other conditions allowed by the Health Department regulations.
- Requires adherence to patient records, PDMP checks, and other safeguards; allows the director to promulgate rules to ensure appropriate management and referrals to specialists when needed.
- Emphasizes that best clinical judgment remains essential and that substance use disorder concerns alone should not block therapeutic prescriptions when clinically appropriate.
- Adds explicit protections for practitioners acting in good faith while allowing disciplinary action for non-therapeutic or unsafe prescribing, dispensing, or record-keeping.
4) Repeal of Intractable Pain Treatment Act (Chapter 5-37.4)
- Repeals the existing Intractable Pain Treatment Act and transfers its scope and provisions into the broader updated framework under the Uniform Controlled Substances Act (Sections 3 and 4 above).
5) General governance and regulatory authority
- Authorizes the Director of Health to promulgate rules and regulations necessary to implement these changes.
- Maintains physician, pharmacy, and hospital roles in controlled substances regulation, with emphasis on patient safety, monitoring, and appropriate clinical discretion.
Impact and who is affected
- Health care practitioners (physicians, osteopaths, dentists, veterinarians, researchers, NP/PA roles in pain management) will operate under updated prescribing, administration, and monitoring requirements.
- Pharmacists, hospitals, and other institutions handling controlled substances will align with revised definitions and regulatory standards.
- Patients receiving opioid therapy (acute pain, cancer-related pain, palliative care, chronic/intractable pain) may experience changes in prescribing limits, monitoring requirements (PDMP checks), and documentation standards.
- State regulatory agencies (Department of Health) gain new regulatory authority to implement and enforce these provisions.
Notes
- The act emphasizes safer opioid use, PDMP integration, and clinician judgment while providing safeguards against improper prescribing and diversion.
- Timeline: Effective upon passage; regulatory rules to be promulgated by the Director of Health as part of implementation.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
